Purified water in the European Pharmacopoeia is defined by monograph 0008 (Aqua purificata), the binding reference for anyone producing, testing or using pharmaceutical-grade water in the European Union. It is by far the most widely used excipient in pharmaceutical manufacturing, yet it remains one of the most contested topics in audits: conductivity limits applied at the wrong temperature, TOC sampled at the wrong point of the loop, microbiological action limits confused with release specifications. In this guide we look at what the monograph actually requires, the numerical limits you need to know by heart, and how the Pharmacopoeia connects to the EMA guideline on the quality of water for pharmaceutical use.
Purified water in the European Pharmacopoeia: what monograph 0008 covers
Monograph 0008 of the European Pharmacopoeia distinguishes two entities with different requirements:
- Purified water in bulk: the water produced and distributed by the plant's treatment system (distribution loop, points of use), intended for the preparation of medicinal products that are not required to be sterile or apyrogenic, unless otherwise justified.
- Purified water in containers: purified water in bulk that is packaged and stored in containers, which must meet additional tests (including acidity/alkalinity, chlorides, sulfates and ammonium) precisely because packaging and storage introduce additional risks.
As for production, the monograph is technology-neutral: purified water is prepared by distillation, ion exchange, reverse osmosis or any other suitable method, starting from water intended for human consumption. The choice of technology is therefore a design and risk-assessment decision, not a compendial obligation — what matters is demonstrating, through qualification and monitoring, that the system consistently produces compliant water.
The monograph limits: conductivity, TOC and nitrates
The physico-chemical requirements for purified water in bulk focus on three parameters measurable in-line or in the laboratory. The table summarises the main limits:
| Parameter | Limit (purified water in bulk) | Operational note |
|---|---|---|
| Conductivity | ≤ 4.3 µS/cm at 20 °C; ≤ 5.1 µS/cm at 25 °C | The limit depends on the measurement temperature: use the monograph table, not a single value |
| TOC (total organic carbon) | ≤ 0.50 mg/L | The oxidisable substances test is accepted as an alternative for water in containers |
| Nitrates | ≤ 0.2 ppm | Colorimetric limit test |
| Aluminium | ≤ 10 ppb | Only if intended for the manufacture of dialysis solutions |
| Bacterial endotoxins | < 0.25 IU/mL | Only if intended for dialysis solutions without a further removal procedure |
Two recurring audit mistakes deserve attention. First: applying the conductivity limit "from memory" without correlating it to the actual measurement temperature of the in-line sensor. Second: treating aluminium and endotoxins as universal requirements — they are not: they apply only when the water is intended for dialysis, and the intended use must be documented.
Microbiological requirements: an action limit, not a specification
On the microbiological side, the monograph sets for purified water in bulk an action limit of 100 CFU/mL, determined by membrane filtration with a nominal pore size not greater than 0.45 µm. This is a decisive conceptual point: it is an action level linked to process control, not a product release specification. The company must define alert and action levels in its monitoring programme consistent with the system's historical data, investigate excursions and demonstrate control over time through trending — exactly what inspectors ask to see, together with excursion management and corrective actions. For purified water in containers, the microbiological acceptance criterion is instead 10² CFU/mL.
Topics like this — compendial limits, monitoring and audit defence — are the daily bread of The Pragmatic GMP, GuideGxP's free weekly newsletter: one operational deep dive per week, with no superfluous theory. Subscribe so you don't miss the next analyses on pharmaceutical water systems.
Purified water, WFI and the right grade for each use
The monograph says what purified water is; where to use it is defined by the EMA guideline on the quality of water for pharmaceutical use (EMA/CHMP/CVMP/QWP/496873/2018, effective 1 February 2021). The fixed points to know:
- sterile parenteral products require Water for Injections (WFI, monograph 0169);
- for sterile non-parenteral products (ophthalmic, nasal) and for non-sterile oral and topical preparations, the minimum grade is purified water;
- the monograph for Highly Purified Water (HPW, 1927) has been suppressed: the intermediate grade no longer exists and applications that used it must be reassigned to WFI or purified water;
- since the 2017 revision of monograph 0169, WFI may also be produced by membrane-based methods — reverse osmosis coupled with techniques such as electrodeionisation or ultrafiltration — and no longer only by distillation, with adequate control of microbiological and biofilm risk.
The required approach is explicitly risk-based: the choice of water grade for each process (including API synthesis steps, where potable water may suffice in the early stages) must be justified in the dossier and supported by the system's controls.
What changes with European Pharmacopoeia 12.3 (July 2026)
The water monographs were revised in European Pharmacopoeia 12.3, applicable from 1 July 2026. The main changes for those managing PW and WFI systems: the TOC limit is now expressed as 0.50 mg/L with an explicit reference to method A of chapter 2.2.44, the metrological requirements for conductivity verification have been clarified and, for sterilised water for injections, the oxidisable substances test has been replaced by TOC with container-size-dependent limits. No revolution, but sampling SOPs and periodic review protocols must be aligned to the new references: citing a superseded monograph text in a validation document is a classic documentation finding.
GuideGxP recommendation
The most effective way to secure compliance with monograph 0008 is to treat it as a system requirement, not a laboratory one. In practice: map the points of use and the intended use of the water at each one (so you apply only the relevant requirements, dialysis included); correlate conductivity limits with the actual measurement temperature of the in-line sensors; define microbiological alert and action levels from historical data, tighter than the compendial limit; document trending through periodic reviews; and verify that SOPs and protocols cite the current edition of the Pharmacopoeia. In audits, the difference is almost always made by the ability to show a system under statistical control, not by a single compliant result.
If you are designing, qualifying or defending a pharmaceutical water system in inspection, GuideGxP's Operational Guide to Pharmaceutical Water and WFI Systems in GMP covers the entire lifecycle — from design basis to periodic review — with a toolkit of ready-to-use templates.
